麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02335 麦科医药-B

休市中 11-13 16:08:15

20.580

-1.100

-5.07%

最高25.300	最低19.410	成交量1,063万
今开21.700	昨收21.680	日振幅27.17%
总市值68.27亿	流通市值57.64亿	总股本3.32亿
成交额2.41亿	换手率3.79%	流通股本2.80亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02335","market":"HK","secType":"STK","nameCN":"麦科医药-B","latestPrice":20.58,"timestamp":1794557295465,"preClose":21.68,"halted":0,"volume":10628400,"delay":0,"changeRate":-0.05073800738007387,"floatShares":280071100,"shares":331740350,"eps":0,"marketStatus":"休市中","change":-1.1,"latestTime":"11-13 16:08:15","open":21.7,"high":25.3,"low":19.41,"amount":241075232,"amplitude":0.271679,"askPrice":20.6,"askSize":40000,"bidPrice":20.58,"bidSize":13200,"shortable":0,"etf":0,"ttmEps":-1.265,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1794792600000},"marketStatusCode":7,"adr":0,"listingDate":1782230400000,"exchange":"SEHK","adjPreClose":21.68,"openAndCloseTimeList":[[1794533400000,1794542400000],[1794546000000,1794556800000]],"volumeRatio":1.1321116474803683,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02335","defaultTab":"news","newsList":[{"id":"2683528036","title":"港股午评|恒生指数早盘跌0.92%    中石油逆市领涨蓝筹股","url":"https://stock-news.laohu8.com/highlight/detail?id=2683528036","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2683528036?lang=zh_cn&edition=full","pubTime":"2026-11-13 12:00","pubTimestamp":1794542431,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数跌0.92%，跌222点，报23786点；恒生科技指数跌1.75%。港股早盘成交935亿港元。中国石油股份涨2.79%，逆市领涨蓝筹。美伊冲突担忧重新升温，公司三季度利润略超预期。国星宇航首挂上市，早盘低开1.85%，午盘收涨1.45%，公司手握114颗待交付AI卫星订单。新秀丽升逾7%，拟斥5000万美元回购。人事风波扰动英伟达生态股，胜宏科技跌8%，中际旭创跌超4%。钧达股份跌6%，公司终止阿曼年产5GW高效电池生产基地项目。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1522718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02833","02335","XOP","DIG","XES","03419","00857","07200","MHImain","PXE","BNO","SPHQ","ERX","03115","OILT","159271","WTIU","83115","09115","513600","HSI","DRIP","159019","07300","GUSH","FTXN","DRLL","KCAI","OILK","VDE","03037","VXUS","HSImain","IEO","OIH","USE","USOI","BCHP","HHImain","02800","06935","PXJ","USL","MCHmain","IXC","XLE","07500","DBC","DBE","OILU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196742793","title":"异动解读｜麦科医药-B盘中上涨4.8%，MT1013Ⅲ期随访完成后资金博弈延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1196742793","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196742793?lang=zh_cn&edition=full","pubTime":"2026-11-13 09:43","pubTimestamp":1794534227,"startTime":"0","endTime":"0","summary":"11月13日，麦科医药-B盘中上涨4.8%，报22.72港元，成交额1473.58万港元。消息面上，市场仍在交易公司核心产品MT1013关键性Ⅲ期临床的阶段性进展。公司此前披露，全部435名受试者已完成研究治疗、方案规定随访并出组，项目进入数据整理及潜在申报准备阶段。该消息已在近日连续引发股价大幅波动，显示资金围绕后续数据读出与申报预期反复博弈；不过公司亦明确提示，仍无法保证MT1013最终成功开发并上市销售。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"麦科医药盘中异动，MT1013Ⅲ期数据博弈升温","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682552273","title":"港股麦科医药-B涨超10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2682552273","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682552273?lang=zh_cn&edition=full","pubTime":"2026-11-12 15:21","pubTimestamp":1794468092,"startTime":"0","endTime":"0","summary":"11月12日，麦科医药-B(02335.HK)涨超10%。截至发稿，涨10.13%，报23.48港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611123929450932.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611123929450932.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","BK4585","02335","BK4588","VXUS","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682552587","title":"港股异动 | 麦科医药-B(02335.HK)再涨超10% 多款创新药研发迎来进展 MT1013完成III期全部受试者入组随访","url":"https://stock-news.laohu8.com/highlight/detail?id=2682552587","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682552587?lang=zh_cn&edition=full","pubTime":"2026-11-12 15:14","pubTimestamp":1794467671,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139201314","title":"异动解读｜麦科医药-B盘中上涨6.29%，MT1013Ⅲ期随访完成后资金博弈延续","url":"https://stock-news.laohu8.com/highlight/detail?id=1139201314","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139201314?lang=zh_cn&edition=full","pubTime":"2026-11-12 10:31","pubTimestamp":1794450707,"startTime":"0","endTime":"0","summary":"11月12日，麦科医药-B盘中上涨6.29%，报22.6港元，成交额3667.37万港元。消息面上，公司核心产品MT1013关键性Ⅲ期临床试验全部435名受试者已完成研究治疗、方案规定随访并出组，项目进入数据整理及潜在申报准备阶段，市场围绕后续读出与申报预期继续交易。此前该进展曾推动股价一度大幅走强，但公司同时提示，仍无法保证MT1013最终成功开发并上市销售。短线来看，股价在前两日回落后再度反弹，反映资金对阶段性临床里程碑的博弈仍在持续。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"麦科医药盘中上涨，MT1013临床完成资金博弈延续","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174911679","title":"异动解读｜麦科医药-B盘中下跌5.1%，MT1013Ⅲ期试验完成治疗随访后资金博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1174911679","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1174911679?lang=zh_cn&edition=full","pubTime":"2026-11-11 09:47","pubTimestamp":1794361649,"startTime":"0","endTime":"0","summary":"11月11日，麦科医药-B盘中下跌5.1%，报21.94港元，成交额1646.18万港元。消息面上，公司核心产品MT1013关键性Ⅲ期临床试验全部435名受试者已完成研究治疗、方案规定随访并出组，项目进入数据整理及潜在申报准备阶段。该进展此前一度推动股价明显冲高，但公司同时提示仍无法保证MT1013最终成功开发并上市销售；在利好阶段性兑现后，短线资金博弈加剧，股价出现回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"麦科医药盘中下跌，MT1013三期收官资金博弈","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105294391","title":"异动解读｜麦科医药-B盘中下跌5.08%，MT1013Ⅲ期试验完成治疗随访后资金博弈加剧","url":"https://stock-news.laohu8.com/highlight/detail?id=1105294391","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105294391?lang=zh_cn&edition=full","pubTime":"2026-11-10 10:19","pubTimestamp":1794277183,"startTime":"0","endTime":"0","summary":"11月10日，麦科医药-B盘中下跌5.08%，报23.18港元，成交额5920.66万港元。消息面上，公司此前披露核心产品MT1013关键性Ⅲ期临床试验中，全部435名受试者已完成研究治疗、全部方案规定随访并出组，意味着项目临床开发取得阶段性进展，后续将进入数据整理及潜在申报准备阶段。不过公司同时提示，仍无法保证MT1013最终能够成功开发并上市销售。此前该消息一度带动股价大幅冲高，在利好兑现后，短线资金博弈加剧，今日盘中出现回落。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"麦科医药-B盘中下跌，MT1013利好兑现资金博弈","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682879335","title":"港股异动 | 麦科医药-B(02335)午后飙升近30% 所有入组参与者完成MT1013的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2682879335","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682879335?lang=zh_cn&edition=full","pubTime":"2026-11-09 13:36","pubTimestamp":1794202602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，麦科医药-B(02335)午后飙升近30%。截至发稿，涨18.98%，报22.38港元，成交额1.54亿港元。消息面上，麦科医药午间发布公告，本公司核心产品MT1013的关键性III期临床试验中，所有入组参与者均已完成研究治疗及所有试验方案规定的随访程序，并已出组。公开资料显示，麦科医药核心产品MT1013为一款全球首创、的双靶点受体激动剂多肽，可同时靶向CaSR及OGP受体，主要用于治疗慢性肾病继发性甲状旁腺功能亢进症，目前已进入III期临床试验阶段。在头对头II期临床试验中，MT1013与已获批药物依特卡肽相比，iPTH、血钙及血磷综合达标率高约2.5倍，三周内起效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1520291.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","VXUS","02335","IBBQ","IBBJ","MDTX","BK4585","BMED","BK1161","KCAI","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104283771","title":"异动解读｜麦科医药-B盘中上涨5.79%，MT1013Ⅲ期临床全部受试者完成治疗及随访","url":"https://stock-news.laohu8.com/highlight/detail?id=1104283771","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104283771?lang=zh_cn&edition=full","pubTime":"2026-11-09 13:01","pubTimestamp":1794200471,"startTime":"0","endTime":"0","summary":"11月9日，麦科医药-B盘中上涨5.79%，报19.9港元，成交额6838.16万港元。消息面上，公司披露核心产品MT1013的关键性Ⅲ期临床试验中，全部435名受试者已完成研究治疗、全部方案规定随访并出组，显示该项目临床开发取得阶段性进展。该进展意味着MT1013距离后续数据整理及潜在申报更进一步。公司同时提示，仍无法保证最终能够成功开发并上市销售该产品，相关研发及商业化仍存在不确定性。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"麦科医药-B上涨，MT1013三期临床完成随访","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137362030","title":"麦科医药-B（02335）披露：核心产品MT1013 Ⅲ期临床研究全部435名受试者完成治疗及随访","url":"https://stock-news.laohu8.com/highlight/detail?id=1137362030","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137362030?lang=zh_cn&edition=full","pubTime":"2026-11-09 12:10","pubTimestamp":1794197449,"startTime":"0","endTime":"0","summary":"2026年11月9日，陝西麥科奧特醫藥科技股份有限公司发布自愿性公告称，其核心产品MT1013的关键性Ⅲ期临床试验全部入组受试者已完成研究治疗及全部试验方案规定的随访程序并出组，标志着该项目临床开发取得阶段性进展。公司同时提醒，依据香港联交所证券上市规则第18A.05条，公司无法保证最终能够成功开发并上市销售MT1013，股东及潜在投资者在买卖公司股份时应审慎行事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682758698","title":"麦科医药-B(02335.HK)：所有入组参与者完成MT1013的III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2682758698","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2682758698?lang=zh_cn&edition=full","pubTime":"2026-11-09 12:08","pubTimestamp":1794197309,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185362540","title":"麦科医药-B（02335）临时股东大会延期至11月20日　过户登记停止期同步延长","url":"https://stock-news.laohu8.com/highlight/detail?id=1185362540","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185362540?lang=zh_cn&edition=full","pubTime":"2026-11-06 22:11","pubTimestamp":1793974282,"startTime":"0","endTime":"0","summary":"麦科医药-B公告称，为让股东有更充足时间审阅拟提呈决议案并作出安排，公司原定于11月10日举行的临时股东大会将顺延至2026年11月20日（周五）上午10时举行，地点不变。同时，原计划11月5日至11月10日暂停的股份过户登记，将延长至11月20日（含当日）。截至11月20日名列公司股东名册的H股及内资股股东，均可出席会议并参与投票。公司董事会确认，除会议日期及股份过户登记时间调整外，通函、通告及委任表格的其他资料均维持不变。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681833602","title":"麦科医药-B盘中涨超30% 已取得MT200605 III期临床试验组长单位伦理批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2681833602","media":"新浪港股","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681833602?lang=zh_cn&edition=full","pubTime":"2026-11-06 11:21","pubTimestamp":1793935260,"startTime":"0","endTime":"0","summary":"按课题任务书及双方合作协议约定，本集团负责MT200605的研发、生产及临床试验供应。于MT200605II期临床试验完成后，本公司已收到本课题首笔中央财政专项经费，并正推动MT200605的临床开发迈向III期。本公司近期已取得MT200605用于治疗急性缺血性卒中患者的III期临床试验组长单位伦理委员会的批准。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-11-06/doc-inixuiyw5035084.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","02335","PSYK","BMED","MDTX","IBBQ","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681384368","title":"港股异动 | 麦科医药-B(02335.HK)再涨超28% 已取得MT200605 III期临床试验组长单位伦理批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2681384368","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681384368?lang=zh_cn&edition=full","pubTime":"2026-11-06 10:54","pubTimestamp":1793933690,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144627877","title":"异动解读｜麦科医药-B盘中上涨23.7%，国家重大专项经费到账叠加Ⅲ期伦理获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1144627877","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144627877?lang=zh_cn&edition=full","pubTime":"2026-11-06 09:45","pubTimestamp":1793929559,"startTime":"0","endTime":"0","summary":"11月6日，麦科医药-B盘中上涨23.7%，报20.88港元，成交额7252.81万港元。消息面上，公司此前披露，MT200605相关课题已收到重大新药创制国家科技重大专项下首笔中央财政经费96万元，并取得急性缺血性卒中Ⅲ期临床试验组长单位伦理批准。上述进展意味着公司核心卒中管线在Ⅱ期达主要终点后，继续向Ⅲ期推进；同时后续经费拨付与课题节点挂钩，强化了市场对研发落地节奏的关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"麦科医药-B大涨，卒中Ⅲ期获批","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681459870","title":"港股异动 | 麦科医药-B(02335)涨近6% 已收到“重大新药创制”国家科技重大专项下首笔课题经费","url":"https://stock-news.laohu8.com/highlight/detail?id=2681459870","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681459870?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:26","pubTimestamp":1793863578,"startTime":"0","endTime":"0","summary":"消息面上，11月4日，麦科医药-B发布公告，本公司与首都医科大学附属北京天坛医院联合承担“重大新药创制”国家科技重大专项下涉及本公司关键产品MT200605的研究课题，且近期已收到本课题首笔中央财政专项经费。本公司亦已取得MT200605 III期临床试验组长单位的伦理批准。本课题为“重大新药创制”国家科技重大专项下设课题(本课题)，由本公司与北京天坛医院联合承担。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","BK4588","VXUS","02335","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147815415","title":"异动解读｜麦科医药-B盘中上涨5.4%，国家重大专项经费到账叠加Ⅲ期伦理获批","url":"https://stock-news.laohu8.com/highlight/detail?id=1147815415","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147815415?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:13","pubTimestamp":1793862814,"startTime":"0","endTime":"0","summary":"11月5日，麦科医药-B盘中上涨5.4%，报16.78港元，成交额5332.63万港元。消息面上，公司公告称，MT200605相关课题已收到国家科技重大专项下首笔中央财政经费96万元，并取得治疗急性缺血性卒中Ⅲ期临床试验组长单位伦理委员会批准。此前该药Ⅱ期临床已完成并达到主要终点，首笔经费将用于支持后续临床研发投入。上述进展意味着核心管线正由Ⅱ期结果向Ⅲ期推进，有助于强化市场对其研发兑现节奏的关注。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"麦科医药-B上涨，脑卒中新药Ⅲ期获批","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680953068","title":"麦科医药-B(02335.HK)收到国家科技重大专项下首笔课题经费及取得MT200605 III期临床试验组长单位伦理批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680953068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680953068?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:02","pubTimestamp":1793804526,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02335","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680506895","title":"麦科医药-B(02335)收到国家科技重大专项下首笔课题经费及取得MT200605 III期临床试验组长单位伦理批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680506895","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680506895?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:02","pubTimestamp":1793804526,"startTime":"0","endTime":"0","summary":"本公司亦已取得MT200605III期临床试验组长单位的伦理批准。首笔专项经费将用于支持MT200605的临床研发投入。于MT200605II期临床试验完成后，本公司已收到本课题首笔中央财政专项经费，并正推动MT200605的临床开发迈向III期。本公司近期已取得MT200605用于治疗急性缺血性卒中患者的III期临床试验组长单位伦理委员会的批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1518711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["PSYK","BMED","IBBJ","02335","MDTX","BK1161","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197708863","title":"麦科医药-B：MT200605获国家重大专项首笔96万元经费并通过Ⅲ期临床组长单位伦理审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1197708863","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197708863?lang=zh_cn&edition=full","pubTime":"2026-11-04 23:01","pubTimestamp":1793804493,"startTime":"0","endTime":"0","summary":"2026年11月4日，陝西麥科奧特醫藥科技股份有限公司发布公告称，其与首都医科大学附属北京天坛医院联合承担的“重大新药创制”国家科技重大专项课题已收到首笔中央财政专项经费人民币96万元，并取得MT200605治疗急性缺血性卒中Ⅲ期临床试验组长单位伦理委员会批准。公司提示，新药研发存在重大风险和不确定性，不保证MT200605最终能够成功开发并实现商业化；后续经费拨付需满足相应课题节点及验收要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02335"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.micot.cn","stockEarnings":[{"period":"1week","weight":0.0941},{"period":"1month","weight":0.2665},{"period":"3month","weight":-0.3061},{"period":"6month","weight":0.1308},{"period":"ytd","weight":0.1308}],"compareEarnings":[{"period":"1week","weight":-0.0345},{"period":"1month","weight":-0.0278},{"period":"3month","weight":-0.0589},{"period":"6month","weight":-0.0896},{"period":"1year","weight":-0.1269},{"period":"ytd","weight":-0.0778}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"陕西麦科奥特医药科技股份有限公司(以下简称“麦科奥特”)于2007年1月在西安成立,现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业,致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业,聚焦于心脑血管、代谢性疾病、炎症疼痛相关疾病新药的研发。公司致力于创制新药、挽救生命,满足未被满足的临床需求,用科技创新为人类健康保驾护航。\n麦科奥特作为一家平台型生物技术公司,致力于加速全球新一代双特异性/多特异性多肽药物的创新及开发,我们的核心产品处于Ⅲ期临床试验。自2007年成立以来,我们专注于代谢性疾病(尤其是肾脏相关疾病)以及心脑血管疾病,作为提出双/多特异性肽技术概念的全球先驱,并凭借进入临床开发的广泛候选产品管线,我们已在该领域确立领先地位。","exchange":"SEHK","name":"麦科医药-B","nameEN":"MICOT PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"麦科医药-B,02335,麦科医药-B股票,麦科医药-B股票老虎,麦科医药-B股票老虎国际,麦科医药-B行情,麦科医药-B股票行情,麦科医药-B股价,麦科医药-B股市,麦科医药-B股票价格,麦科医药-B股票交易,麦科医药-B股票购买,麦科医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"麦科医药-B(02335)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供麦科医药-B(02335)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}